Disc Medicine (IRON) said late Wednesday it priced its public offering of common stock and pre-funded warrants for gross proceeds of about $225.5 million, upsized from the initial offering of $200 million.
The company said it is selling about 3.9 million shares and pre-funded warrants to purchase 181,818 shares. The common shares are being sold at $55 per share, while the warrants are being sold at $54.9999 per warrant.
Underwriters have been granted a 30-day option to purchase up to about $33.8 million additional shares.
Proceeds from the offering, set to close on Friday, would be used to fund research and clinical development of its product candidates, support the potential commercialization of bitopertin for erythropoietic protoporphyria and X-linked protoporphyria, and for general corporate purposes, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.